



## Procaps Group Update on Third Quarter Results

November 14, 2023

MIAMI & BARRANQUILLA, Colombia--(BUSINESS WIRE)--Nov. 14, 2023-- Procaps Group (NASDAQ: PROC) ("Procaps"), a leading integrated LatAm healthcare and pharmaceutical services company, today announced that it is postponing the previously-announced earnings conference call (currently scheduled for November 16, 2023) to a later date after Procaps publishes its results for the third quarter and nine months ended September 30, 2023 ("3Q23"). Procaps will host a conference call in conjunction with its release of the 3Q23 Results, and call/webcast details will be provided in advance of the call.

### About Procaps Group

Procaps Group, S.A. ("Procaps") (NASDAQ: PROC) is a leading developer of pharmaceutical and nutraceutical solutions, medicines, and hospital supplies that reach more than 50 countries in all five continents. Procaps has a direct presence in 13 countries in the Americas and more than 5,500 employees working under a sustainable model. Procaps develops, manufactures, and markets over-the-counter (OTC) pharmaceutical products and prescription pharmaceutical drugs (Rx), nutritional supplements and high-potency clinical solutions.

For more information, visit Procaps' investor relations website [investor.procapsgroup.com](https://investor.procapsgroup.com).

View source version on [businesswire.com](https://www.businesswire.com/news/home/20231114580770/en/): <https://www.businesswire.com/news/home/20231114580770/en/>

### Investor Contact:

Melissa Angelini

[ir@procapsgroup.com](mailto:ir@procapsgroup.com)

[investor.procapsgroup.com](https://investor.procapsgroup.com)

Source: Procaps Group, S.A.